PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil
Diagnostics · 09.03.2023 · 13 (6) · 1041
DOI: 10.3390/diagnostics13061041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 09.03.2023. Verfasst von Bruna Pereira Sorroche und 6 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), National Council for Scientific and Technological Development (CNPq).
Abstract (Originalsprache)
Immune checkpoint blockade (ICB) agents are prominent immunotherapies for the treatment of advanced melanoma. However, they fail to promote any durable clinical benefit in a large cohort of patients. This study assessed clinical and molecular predictors of ICB response and survival in advanced melanoma. A retrospective analysis was performed on 210 patients treated with PD-1 or CTLA-4 inhibitors at Barretos Cancer Hospital, Brazil. PD-L1 expression was assessed by immunohistochemistry using formalin-fixed paraffin-embedded tumor tissues collected prior to ICB therapy. Patients were divided into responders (complete and partial response and stable disease for more than 6 months) and non-responders (stable disease for less than 6 months and progressive disease). Among them, about 82% underwent anti-PD-1 immunotherapy, and 60.5% progressed after the ICB treatment. Patients that received ICB as first-line therapy showed higher response rates than previously treated patients. Higher response rates were further associated with superficial spreading melanomas and positive PD-L1 expression (>1%). Likewise, PD-L1 positive expression and BRAF V600 mutations were associated with a higher overall survival after ICB therapy. Since ICBs are expensive therapies, evaluation of PD-L1 tumor expression in melanoma patients should be routinely assessed to select patients that are most likely to respond.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil.
- Department of Clinical Oncology, Barretos Cancer Hospital, Barretos 14784-400, Brazil.
- Department of Pathology, Barretos Cancer Hospital, Barretos 14784-400, Brazil.
- UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15260, USA.
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA 15260, USA.
- Melanoma, Sarcoma, and Mesenchymal Tumors Surgery Department, Barretos Cancer Hospital, Barretos 14784-400, Brazil.
ORCID-Profile: Bruna Pereira Sorroche, Lazar Vujanovic, Lidia Maria Rebolho Batista Arantes
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
- National Council for Scientific and Technological Development (CNPq)
Zitieren
APA
Sorroche, B. P., Teixeira, R. J., Pereira, C. A. D., Santana, I. V. V., Vujanovic, L., Vazquez, V. L., & Arantes, L. M. R. B. (2023). PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil. Diagnostics, 13(6), 1041. https://doi.org/10.3390/diagnostics13061041
Vancouver
Sorroche BP, Teixeira RJ, Pereira CAD, Santana IVV, Vujanovic L, Vazquez VL, et al. PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil. Diagnostics. 2023;13(6):1041. doi:10.3390/diagnostics13061041
BibTeX
@article{Sorroche2023,
author = {Sorroche, Bruna Pereira and Teixeira, Renan de Jesus and Pereira, Caio Augusto Dantas and Santana, Iara Viana Vidigal and Vujanovic, Lazar and Vazquez, Vinicius de Lima and Arantes, Lidia Maria Rebolho Batista},
title = {PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil},
journal = {Diagnostics},
year = {2023},
volume = {13},
number = {6},
pages = {1041},
doi = {10.3390/diagnostics13061041}
}
EUVIMED